Back
Speaker illustration

undefined undefined undefined

Presentations

Delphi study of management of patient with HFrEF in Spain: post-discharge follow-up of a patient with an episode of WHF

Event: Heart Failure 2025

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: ePosters in chronic heart failure - heart failure with HFrEF (1)

Access
Like
Thumbnail

Can we expect results in addition to the paradigm and provide trial with use of Sacubitril/Valsartan in a real life cohort?

Event: Heart Failure 2021

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: ePoster session

Access
Like
Thumbnail

Laboratory value-based innovation in heart failure can improve patient health-related outcomes

Event: Heart Failure 2021

Topic: Biomarkers

Session: ePoster session

Access
Like
Thumbnail

Is it possible the use of sacubitril/valsartan in HFrEF and hemodialysis?

Event: Heart Failure 2018

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Access
Like
Thumbnail

Sodium-glucose co-transporter-2 inhibitors as oral antidiabetic in patients wit heart failure

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: co-morbidities (other)

Session: Comorbodities

Access
Like
Thumbnail

It is possible to avoid an ICD implantation with empagliflozine?

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Chronic heart failure

Session: Clinical Case Corner 3 - Metabolic issues in heart failure: don't forget periphery!

Access
Like
Thumbnail

Use of ISGLT-2 in Diabetes Mellitus type 2 and heart failure

Event: EuroPrevent 2017

Topic: Diabetes

Session: Diabetes/ Lipids/Obesity/Nutrition_Part 1

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources